ライフサイエンスコーパス: administration schedule

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 andidates, and provides a convenient monthly administration schedule.

2 ee times weekly for 4 weeks using a standard administration schedule.

3 plastic agents but was highly dependent upon administration schedule.

4 cal in packaging, labelling, appearance, and administration schedule.

5 with depsipeptide should examine alternative administration schedules.

6 natomic regions, risk levels, and antiemetic administration schedules.

7 al, dictated a change in dose escalation and administration schedules.

8 with allowance for evaluation of alternative administration schedules.

9 h favorable toxicity profiles and convenient administration schedules.

10 n with WT is no less effective than the long administration schedule and can be administered at a sub

11 Administration schedule and dose of Synthokine were eval

12 fine chemopreventive activity, optimal dose, administration schedule, and toxicity for the coxibs in

13 g regimens are toxic, they require demanding administration schedules, and resistant viruses can emer

14 owth inhibition/growth delay over a repeated administration schedule at well-tolerated doses.

15 th RAD001, a rapamycin derivative, showed an administration schedule-dependent increase in activation

16 With either administration schedule, dose escalation should be consi

17 that identifies in silico the most effective administration schedule for gemcitabine monotherapy.

18 The short administration schedule for the treatment of children wi

19 e trials aimed at identifying more effective administration schedules for doxycycline are warranted.

20 he emergence of resistance, and optimum drug administration schedules for patient populations at risk

21 Parenteral administration schedules have been evaluated because of

22 ework significantly changes the optimum drug administration schedules identified, often predicting no

23 ther antineoplastic agents in four different administration schedules in A549 human non-small cell lu

24 ility after oral and 2-hour intravenous (IV) administration schedules in patients with malignancy.

25 Few practices changed their administration schedules in response to revised recommen

26 d a bone marrow-sparing effect when a weekly administration schedule is used.

27 study was undertaken to evaluate the optimum administration schedule of pemetrexed and gemcitabine in

28 determine the efficacy, safety, and optimal administration schedule of rituximab with fludarabine in

29 Adoption of an intermittent administration schedule of this cytokine could be more e

30 million immunized children, but its current administration schedule of two doses given a year apart

31 m-tolerated dose (MTD) of BMS-184476 on this administration schedule, only one heavily pretreated pat

32 ured) received lidocaine or saline on 1 of 4 administration schedules (preinjury only, postinjury onl

33 phase II evaluations of penclomedine on this administration schedule should be focused on specific di

34 re partially alleviated through altering the administration schedule to nighttime dosing.

35 The identification of optimal drug administration schedules to battle the emergence of resi

36 MPO regardless of administration schedule (twice a day or every day) signi

37 In the present investigation, a longer administration schedule was used, which encompasses both

38 Docetaxel administration schedules were as follows: schedule A, on

39 Two docetaxel administration schedules were studied, with the drug adm

40 These results highlight the importance of administration schedule when combining flavopiridol with

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。